The effect of sulthiame on potential biomarkers in moderate to severe obstructive sleep apnoea.

ABSTRACT:

Background

Obstructive sleep apnoea (OSA) is a common disease with breathing disturbances during sleep. Sulthiame (STM), a carbonic anhydrase (CA) inhibitor, was recently shown to reduce OSA in a significant proportion of patients. CA activity and hypoxia-inducible factor (HIF)-1α are two potential biomarkers reported in severe OSA and hypoxia. Both have been considered to play roles in the development of OSA comorbidities. This study investigated the effects of STM on these biomarkers in OSA.

Methods

This was an exploratory analysis of a randomised, double-blind, placebo-controlled trial of STM in OSA. Patients with moderate to severe OSA, body mass index 20-35 kg·m^-2, aged 18-75 years and not accepting positive airway pressure treatment were randomised to 4 week

SUBMITTER: Hoff E 

PROVIDER: S-EPMC11610040 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature